Immunocore Holdings plc (IMCR)
IMCR trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1671927/000167192726000005/0001671927-26-000005-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | IMCR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United Kingdom |
| IPO year | 2021 |
| SEC CIK | 0001671927 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | United Kingdom |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $400.0M |
| Net income | -$35.5M |
| Operating income | -$45.4M |
| Net margin | -8.9% |
| Operating margin | -11.3% |
| Revenue growth | +29.0% |
| Cash | $467.7M |
| Total assets | $1.1B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-06 |
| Cash and burn | $512.2M cash; operating cash flow -$2.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 51,681,376 (2026-10-31); 50,530,419 a year earlier; 49,820,613 three years earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte LLP, Cambridge, United Kingdom | PCAOB Form AP 2026-03-19 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $5.6M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $102.2M | -$14.2M | $20.1M | $512.2M | No debt tags | $429.3M | 10-Q 2026-11-06 |
| Q2 2026 2026-06-30 | $115.9M | -$808K | $15.9M | $484.9M | No debt tags | $430.8M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $106.7M | $13.0M | -$13.8M | $452.7M | No debt tags | $412.8M | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $104.5M | -$30.1M | -$32.7M | $467.7M | No debt tags | $400.0M | 10-K 2026-02-25 |
| Q3 2025 2025-09-30 | $103.7M | -$177K | -$4.5M | $498.4M | No debt tags | $379.6M | 10-Q 2026-11-06 |
| Q2 2025 2025-06-30 | $98.0M | -$10.3M | $26.0M | $487.9M | No debt tags | $356.1M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $93.9M | $5.0M | $435K | $476.8M | No debt tags | $333.6M | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $84.1M | -$23.8M | -$14.0M | $455.7M | No debt tags | $310.2M | 10-K 2026-02-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document 427B7 | 424B7 | 2025-03-17 |
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-11-06 |
| Latest current report | 8-K | 2026-11-06 |
| Latest proxy | DEF 14A | 2026-04-16 |
Source: SEC EDGAR submissions feed, 283 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.4% |
| 1 month | +7.6% |
| 3 months | -12.5% |
| Year to date | -13.7% |
| 1 year | -15.4% |
| From 52-week high | -25.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LYCA | Lycia Therapeutics Inc. | $28.61 | -8.30% | $1.5B |
| MESO | Mesoblast Limited | $12.45 | -6.18% | $1.6B |
| VIR | Vir Biotechnology Inc. | $9.58 | -3.82% | $1.6B |
| NVAX | Novavax Inc. | $8.06 | -5.45% | $1.3B |
| TSHA | Taysha Gene Therapies Inc. | $4.06 | -0.98% | $1.3B |
| ALVO | Alvotech | $4.41 | +5.13% | $1.7B |
| WWB | Windward Bio Group AG Common Shares | $30.04 | +5.40% | $1.7B |
| RXRX | Recursion Pharmaceuticals Inc. | $2.90 | -8.79% | $1.8B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier